EcoDrugPlus

Prostaglandin D2 Receptor 2

Ensembl ID : ENSGACG00000018425
Gene Symbol: PTGDR2
1 Cross references
145 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSGACG00000019959
Gene Symbol: PTGDR2
1 Cross references
133 Possible Orthologues:

Prostaglandin E Receptor 1a (Subtype Ep1)

Ensembl ID : ENSGACG00000019103
Gene Symbol: PTGER1A
1 Cross references
171 Possible Orthologues:

Prostaglandin E Receptor 1b (Subtype Ep1)

Ensembl ID : ENSGACG00000006265
Gene Symbol: PTGER1B
1 Cross references
163 Possible Orthologues:

Prostaglandin E Receptor 2a (Subtype Ep2)

Ensembl ID : ENSGACG00000014102
Gene Symbol: PTGER2A
1 Cross references
203 Possible Orthologues:

Prostaglandin E Receptor 3

Ensembl ID : ENSGACG00000009453
Gene Symbol: PTGER3
1 Cross references
196 Possible Orthologues:

Prostaglandin E Receptor 4 (Subtype Ep4) A

Ensembl ID : ENSGACG00000006542
Gene Symbol: PTGER4A
1 Cross references
202 Possible Orthologues:

Prostaglandin E Receptor 4 (Subtype Ep4) B

Ensembl ID : ENSGACG00000015930
Gene Symbol: PTGER4B
1 Cross references
202 Possible Orthologues:

Prostaglandin F Receptor (Fp)

Ensembl ID : ENSGACG00000011963
Gene Symbol: PTGFR
1 Cross references
195 Possible Orthologues:

Prostaglandin I2 Receptor

Ensembl ID : ENSGACG00000009600
Gene Symbol: PTGIR
1 Cross references
188 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSGACG00000016097
Gene Symbol: PTGS1
2 Cross references
196 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSGACG00000013921
Gene Symbol: PTGS1
1 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).